Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
from RTT - Top Story https://ift.tt/uT5bQpH
via IFTTT
from RTT - Top Story https://ift.tt/uT5bQpH
via IFTTT
Comments
Post a Comment